Corcept Therapeutics Inc. (0001088856) has filed a Form 144 with the Securities and Exchange Commission, indicating a significant move by the company’s insiders or affiliates. Form 144 is required to be filed with the SEC when insiders, affiliates, or shareholders plan to sell their company shares. The filing allows the public to be informed about potential sales of restricted or control securities.
Corcept Therapeutics Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of severe metabolic, psychiatric, and oncologic disorders. The company’s primary product, Korlym, is approved for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome. For more information about Corcept Therapeutics Inc., you can visit their website here.
Form 144 filed by Corcept Therapeutics Inc. signifies a potential sale of securities by insiders or affiliates of the company. Investors and the public can track these filings to stay informed about any significant developments within the company regarding share sales.
Read More:
Corcept Therapeutics Inc Submits SEC Filing Form 144 – Find Out More Here
Leave a Reply